SPMS

News

Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.

News

Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.